

# Q2 REPORT

Daniel Öhman, CEO Tobias Linebäck, CFO and dep. CEO



## **Agenda**





## Strong Q2 growth

Revenues 212 (201) EBITDA 18 (18) EBIT 12 (12)
Organic growth 6% Margin 8% Margin 6%

- Continued strong organic growth.
- The strong growth is generally converted to higher profitability in the clinics.
- Profitability affected by less demand in VGR and lower proportion of patients needing surgery.



## Factors behind the Q2 performance

#### General

- Good growth in Stockholm and Skåne. Less growth in VGR and Dental.
- Most clinics in Stockholm deliver strong results.
- Surgery has decreased in frequency.
- Orthopaedic day surgery is an area which is highly competitive.

#### **Specific**

- Another excellent quarter from our clinics at Sophiahemmet and Ortho Center Stockholm.
- Ortho Center Göteborg affected by inconsistent requests from county council.
- Dental still hasn't caught up to last year but we should see that changing during H2.






## **Agenda**






## **Organic growth continues**





## Healthy split between revenue sources

#### Revenue Distribution





### **Business Area Nordic**

- Solid performance for both periods, but projects to increase financial performance continue
- Strong patient pressure in Stockholm. Projects ongoing to increase capacity
- Uneven demand from Västra Götalandsregionen

MSEK	Q2 2015	Q2 2014	Change %	6 m 2015	6 m 2014	Change %
Revenue	208	197	6	423	400	6
EBITA	12	11		25	27	
EBITA margin, %	6	6		6	7	




### **Business Area Rest of the World**


- Management contract for diabetes clinic and business development for more activities
- Financial performance affected by large business development costs and UK process

MSEK	Q2 2015	Q2 2014	Change %	6 m 2015	6 m 2014	Change %
Revenue	4	4	-10	7	8	-8
EBITA	0	1		1	2	
EBITA margin, %	0	28		14	26	



## Revenue development – secondary segments 6 months







## **Key figures**

#### **Comments**

- Continued strong key figures
- Significant business development capacity

SEK millions	H1 2015	H1 2014
EBITDA	38	41
EBT	24	27
EPS	21 öre	26 öre
Return on equity	8,7%	neg
Net Debt	57	50
Net Debt / EBITDA	1,00	1,03
Equity Ratio	52	50




### Cash flow 2015

#### **Comments**

- Similar cash flow from operations before changes in working capital
- Bank repayment (26 MSEK) in Q2 2015 impacts total cash flow
- Included in Financing is also payment for minority shares (20 MSEK in Q2) and dividend payments

MSEK	Q2	Q2	6 m	6 m
	2015	2014	2015	2014
Op cash flow before changes in w/c	12,4	11,4	26,3	26,7





## **Agenda**





## New business in integrated care solutions

- There is a strong need to get healthcare costs under control due to increased demand and limited funds
- GHP's business model already give more care for each krona spent on healthcare
- We can do more by developing pathways from a value based perspective but it demands new ways of working together with our customers
- GHP uniquely positioned to do this and has started a new company to work with this
- First example is our collaboration with Skandia
- The new business will not translate to any profit this year







## Other developments

#### **Growth**

- Acquisition and start-up projects continue
- Political risk
- The majority has issued a recommendation urging the Government to change the focus of the inquiry

#### **Staff**

- New Business Area Manager Max van Eijk
- New CEO for our clinics at Sophiahemmet Rein Seensalu

#### **Knowledge about GHP**

 Capital Markets Day (3 September), new homepage and marketing material

## www.ghp.se

#### Contact.

Daniel Öhman, CEO | +46 708 55 37 07 | daniel.ohman@ghp.se

Tobias Linebäck, CFO and IR | +46 708 55 37 19 | tobias.lineback@ghp.se

